(RG9) Molecular Interactions Research Group (MIRG)

Similar documents
Research Group (MIRG)

Molecular Interactions Research

The MIRG 2002 Study: Assembly State, Thermodynamic and Kinetic Analysis of an Enzyme/Inhibitor Interaction

Characterization of Small Molecule to Protein Binding

Application of label-free technologies in a core facility research. Ewa Folta-Stogniew Yale University

BA, BSc, and MSc Degree Examinations

Biophysics Core Ewa Folta-Stogniew, Ph.D., M.S.

The use of surface plasmon resonance to guide the choice of nucleic acid oligomers for co-crystallisation with proteins

The World Leader in SPR Technology. Jimmy Page, PhD, Biacore, Inc.

ARBRE-P4EU Consensus Protein Quality Guidelines for Biophysical and Biochemical Studies Minimal information to provide

SURFACE PLASMON RESONANCE-BASED SYSTEMS

Biophysical characterization of proteinprotein

Basic Biacore Course. Introduction to SPR technology. Biacore Training

Improving biosensor analysis

ProteOn XPR36 Quantikinetics: Antibody Concentration and Detailed Kinetic Analysis in a Single Experimental Cycle

protein interaction analysis tech note 5367

Supplementary methods

Enhance Your Protein Interaction Research with A New Level of Bench-Top Productivity

Regulatory Consideration for the Characterization of HOS in Biotechnology Products

protein interaction analysis

Surface plasmon resonance

IMPACT OF HIGHER ORDER COMPLEXES ON BIOMARKER TARGET QUANTITATION

Size-exclusion chromatography TT30 sample was analyzed using a Tosoh Haas TSK Gel G3000SW XL 7.8 mm 30cm column at 1 ml/min and 280 nm detection.

AC Immune SA, Lausanne, Switzerland *For correspondence:

Antigens & Antibodies II. Polyclonal antibodies vs Monoclonal antibodies

GE Biacore T Check that the waste bottle is empty.

University of Bristol - Explore Bristol Research

BIA Experimental Designs

Label-Enhanced SPR Improves the Detectability of Label-Free Surface Plasmon Resonance Analysis 100x

Please note that in order to obtain useful results, the input values should be in the correct units (as indicated per input cell).

Biacore X100. GE Healthcare Life Sciences. Biacore X100 Plus Package. Biacore X100 delivers:

SUPPLEMENTARY INFORMATION

GE Healthcare Life Sciences. A year of interaction with Biacore X100

Real-Time Biomolecule Interaction Analysis Biacore

Characterisation of proteins

Chapter 6. Techniques of Protein and Nucleic Acid Purification

GE Healthcare Life Sciences. Label-free interaction and stability analysis in vaccine design and development

Case Studies ZoBio

Fast Trak Services: a collaborative project to accelerate downstream biosimilar process development

Reflected light a b. prism. flow chamber. flow chamber

Supplementatry Fig 1. Domain structure, biophysical characterisation and electron microscopy of a TD. (a) XTACC3/Maskin and XMAP215/chTOG domain

Label-free interaction analysis in realtime using surface plasmon resonance

Fig. 1. A schematic illustration of pipeline from gene to drug : integration of virtual and real experiments.

Explore the future. Automotive Test Systems Process & Environmental Medical Semiconductor Scientific

protein interaction analysis tech note 5540

High-throughput Biophysical Analysis of Protein Stability: Comparability Assessments and Formulation Development

Case Study: A Phase-Driven Approach to the Development and Lifecycle Management of Potency Assays. Spring in New England!!!

Phage Antibody Selection With Reichert SPR System

Nature Structural & Molecular Biology: doi: /nsmb.2548

A quantitative investigation of linker histone interactions with nucleosomes and chromatin

LARGE-SCALE PROTEIN INTERACTOMICS. Karl Frontzek Institute of Neuropathology

Validation of a concentration assay using Biacore C

PHF20 is an effector protein of p53 double lysine methylation

Characterization of Aptamer Binding using SensíQ SPR Platforms

Biosensing Probe for Quality Control Monitoring of the Structural Integrity of Therapeutic Antibodies

Sensitive protein:ligand biochemical assays using Corning Epic label-free technology on the EnSpire Multimode Plate Reader

Better Living Through Biosensors

Precise. Flexible. Robust. Affordable.

Chapter 5: Proteins: Primary Structure

BIOCHEMISTRY 551: BIOCHEMICAL METHODS SYLLABUS

Ligand immobilization using thiol-disulphide exchange

Talk with the editors of THE JOURNAL OF BIOLOGICAL CHEMISTRY

AME-133: A Next-Generation Anti-CD20 Engineered for Enhanced Killer Function

Ewa Folta-Stogniew. Biophysics Resource; Keck Laboratory Yale School of Medicine

MACROMOLECULAR AFFINITY CHARACTERIZATION FACILITY. India. There are 4 instruments in the facility. They are Biacore2000,

Structure of a novel phosphotyrosine-binding domain in Hakai that targets E-cadherin

Calcium binding proteins in malaria and heart disease

Characterization of drug-plasma protein interactions using surface plasmon resonance

Biomarker Discovery using Surface Plasmon Resonance Imaging

Supplementary Materials. for. array reveals biophysical and evolutionary landscapes

Fluorescent protein. Origin of fluorescent proteins. Structural and biophysical analysis of FPs. Application in molecular biology and biotechnology

Solvent Correction versus In-line Reference Measurement

Lecture 25: Introduction to Chromatography and Gel Filtration

Introduction to Protein Purification

Supplementary Table 1: List of CH3 domain interface residues in the first chain (A) and

Question 2 (15 points)

Biacore The high performance research system. Work with high sensitivity

May 16-18, 2011 Beijing, China. Mark Rosolowsky, Ph.D. Vice President, Bristol-Myers Squibb

Protein Interaction Analysis

Label-free Assays in a Drop. Protein Presence. Quantitation. Kinetics. Assay Development.

Comparability Analysis of Protein Therapeutics by Bottom-Up LC-MS with Stable Isotope-Tagged Reference Standards

Neutralising Assay Methodologies

Metabolomics Research Group

Immunotoxicology Technical Committee (ITC) HESI Assembly of Members January 19, 2009

Lecture FO7 Affinity biosensors

Supplementary Information for. hnrnp Q mediates a phase-dependent translation-coupled mrna decay of mouse. Period3.

Label-free Assays in a Drop. Protein Presence. Quantitation. Kinetics. Assay Development.

20.320, notes for 9/18

High affinity target binding: a cause of non-linear Pharmacokinetics of drugs (Target mediated drug disposition: TMDD)

Supplementary Materials: A Toolbox of Genetically Encoded FRET-Based Biosensors for Rapid L-Lysine Analysis

Supplementary Table Janssen et al.

Phi29 Scaffold Has a Helix-Loop-Helix Motif and a Disordered Tail. Marc C Morais et al., Nature Structural Biology 2003

Assistant Professor Mohammad A Alsenaidy, MSc, PhD, Saudi Arabia

Antibody-drug Conjugates: Characterization and Control Strategies of Lysine-linked Products

protein interactions tech

Biotherapeutics Interest Group Workshop 64th ASMS Conference and Allied Topics, June 5 - June 9, 2016, San Antonio, TX

AAPS Short Course: Characterization Methods for Aggregates and Particles in Peptide and Small Protein Formulations

5.36 Biochemistry Laboratory Spring 2009

SUPPLEMENTARY MATERIAL

T H E J O U R N A L O F C E L L B I O L O G Y

Transcription:

(RG9) Molecular Interactions Research Group (MIRG) Aaron P. Yamniuk, John Newitt, Fumio Arisaka, Anthony Giannetti, Preston Hensley, David Myszka, Fred Schwarz, Ed Eisenstein, Michael Doyle ABRF 2013 Palm Springs CA March 4, 2013 Session Organizer: Aaron Yamniuk, Bristol-Myers Squibb 1

Session Outline Session 1: Introduction to a Protein Interaction System used for Quantitative Evaluation of Biomolecular Interactions Aaron Yamniuk, Bristol-Myers Squibb Session 2: Results of the MIRG 2012 Benchmark Study on Quantitative Evaluation of a Protein-Protein Interaction Satya Yadav, Cleveland Clinic Lerner Research Institute 2

MIRG Mission To show how biophysical tools (biosensor, ITC and AUC) are used to quantitatively characterize molecular interactions To show how these tools work in a resource facility environment To educate the ABRF members in the methodologies of the three core technologies To provide test systems to be used to compare the capabilities of individual laboratories with each other, either within the three disciplines or among the disciplines To compile the results of the analyses of these systems and publish the results in the Journal of Biomolecular Techniques or other appropriate publications To meet regularly to organize and run workshops or other activities at the annual ABRF meetings to accomplish this mission A + B AB AUC ITC SPR 3

Past MIRG Benchmark Studies MIRG 2002 Benchmark Study: Quantitative analysis of Enzyme/Inhibitor interaction 4-Carboxybenzenesulfonamide (201.2 Da) MIRG 2010 Benchmark Study: Molecular Interactions in a Three- Component System protein B protein C kinetics & affinity protein A?? Carbonic Anhydrase II (~30,000 Da) PDB:112CA Ternary complex? Competitive binding? For more information see: www.abrf.org/mirg 4

MIRG Objective: Develop a protein-protein p interaction system to test limits of core molecular interaction technologies Use system to: Test limits of MIRG core interaction technologies Evaluate new molecular interaction technologies Possible future use as a reference standard for core laboratories? Desired properties: Easy production with good yield High solubility and stability Desired affinity range of K D = ~10-9 10-5 M can we use one molecule pair to test high and low end? High resolution structures for computational analysis 5

MIRG Plan: Evaluate the use of the (mutant) Barnase/Barstar protein interaction system Barnase (or mutant Barnase) K ~10-3 -14 D 10 M Barstar (or mutant t Barstar) Well characterized proteins (structure, t folding, binding) (Hartley, Fersht, others) Easy production with high yield Favorable stability and solubility properties Large collection of mutants available (K D 10-3 10-12 M) 6

Construct design to generate bivalent interaction with desired affinities his-binase1 his-binase2 R59A R59A K d ~10-8 10-9 M K d ~10-5 10-6 M d Also produce wild type for comparison (~10x higher affinity) Y29A his-barstar*-y29a (Y29A, C40A, C82A) wild type his-barstar* (C40A, C82A) 7

Production of barstar and binase proteins Protein Predicted Mass (g/mol) a Theor. pi ESI/TOF Mass (g/mol) DLS Rh (nm) b SEC-MALS (g/mol) His-Barstar 12,031 5.3 12,030 1.8 ± 0.0 12,300 His-Barstar-Y29A 11,939 5.3 11,939 1.9 ± 0.1 11,800 His-Binase1 26,283 8.5 26,284 2.6 ± 0.1 26,700 His-Binase2 26,283 8.5 26,284 2.6 ± 0.1 27,300 0.5, 2.0, 10ug His-binase1 Barstar 10,205 4.9 10,205 1.6 ± 0.1 10,100 Barstar-Y29A 10,112 4.9 10,112 1.6 ± 0.1 9,790 Binase1 24,434 8.8 24,434 2.2 ± 0.2 24,900 Binase2 24,434 8.8 24,434 2.3 ± 0.1 24,800 0.5, 2.0, 10ug His-barstar-Y29A Protocols developed for efficient expression, purification, and his-tag cleavage (E. Eisenstein, J. Newitt) Proteins are high purity, monomeric in solution with expected mass 8

ITC: Barstar*-Y29A vs Binase1 or 2 5.00 Time (min) 0 30 60 90 120 1E-4 1E-5 K o d values (25 C) Av ± SD 4.80 µcal/sec 4.60 4.40 4.20 Kd (M) 1E-6 1E-7 1E-8 High affinity site Low affinity site 0.00 1E-9 KCal/Mole of Inje ectant -2.00-4.00-6.00-8.00 R59A, -0.5 0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 4.5 5.0 Molar Ratio - Tested multiple concentrations, temperatures (18 measurements, 3 laboratories) - N = 2.0, highly reproducible (full activity) - his-tagged was equivalent to untagged - Binase1 was equivalent to binase2 - Reproducible K D determination possible 9 but challenging

AUC: Barstar*-Y29A vs Binase1 or 2 Data at low [protein] Protein Kd1 (nm) Kd2 (um) domain Binase 1 10-40 46 Binase 1 5-15 16-20 Binase 2 10-40 Additional measurements in progress Data at high [protein] R59A, domain - Tested multiple loading concentrations, 2 rotor speeds (sedimentation ti equilibrium) i -K D values in agreement with ITC 10

SPR: Barstar*-Y29A vs Binase1 or 2 1E-3 1E-4 Av ± SD Kd (M) 1E-5 Triplicate measurements 1E-6 1E-7 High affinity site Low affinity site R59A, 1E-8 - Tested multiple analyte concentrations, & surface densities (20 measurements, 3 labs) - his-tagged was equivalent to untagged - Binase1 was equivalent to binase2 - Reproducible K D determination ti possible but challenging 11

Comparison: ITC vs AUC vs SPR Barstar*-Y29A vs Binase1 or 2 High affinity site 1E-3 Low affinity site 1E-6 1E-7 1E-4 Av ± SD Kd d (M) 1E-8 Kd (M) 1E-5 1E-9 ITC AUC SPR (amine) 1E-6 ITC AUC SPR (amine) Significantly higher affinity determined by ITC compared to SPR for each site AUC agrees well with ITC for higher affinity site, intermediate between ITC and SPR values for lower affinity site Why do different techniques give different K D values for this protein-protein interaction? 12 Solution vs surface effects?

Does amine-coupling impact affinity? SPR using his-tag capture: Barstar*-Y29A vs Binase1 or 2 R59A, Anti-his Fab R59A, Density (RU) K D 1 (nm) K D 2 (um) his-binase2 315 57 33 his-binase2 450 48 29 his-binase2 640 54 31 - Oriented his-binase surface - Both sites = higher affinity compared to amine-coupling. 13

Summary of all data 1E-6 High affinity site 1E-3 Low affinity site 1E-7 1E-4 Av ± SD Kd K (M) 1E-8 Kd (M) 1E-5 1E-9 ITC AUC SPR (amine) SPR (anti-his) 1E-6 ITC AUC SPR (amine) SPR (anti-his) Different affinities determined using solution and surface-based measurements amine-coupling appears to influence affinity because his-capture experiments = higher affinity Surface electrostatic effects may also contribute to lower SPR affinity compared to solution-based measurements See Yamniuk et al, manuscript in preparation 14

Conclusions: Protocols in place for high yield production of barstar and binase proteins Barstar/binase proteins have suitable biophysical properties for use in benchmarking (high solubility, stability, fractional activity) Barstar*-Y29A / binase interaction has affinities in the desired range to test the limits of label-free interaction technologies Affinities appear Challenging to obtain Different for surface (SPR) vs solution (ITC/AUC) binding, but reproducibly obtained using a given technique System t suitable for benchmark study (see MIRG2012 Benchmark study results)? Possible future use as a reference standard for core laboratories? 15

Acknowledgements MIRG Members Simon Bergqvist, Pfizer Mike Doyle, Bristol-Myers Squibb Satya Yadav, Cleveland Clinic Aaron Yamniuk (Chair), Bristol- Myers Squibb Thomas Neubert (EB liaison), New York University School of Medicine Collaborators Ed Eisenstein, University Maryland John Newitt, Bristol-Myers Squibb Fumio Arisaka, Tokyo Institute of Technology Anthony Giannetti, Genentech Inc Preston Hensley, Lotus Translational Medicine David Myszka, University of Utah Fred Schwarz, National Institute of Standards and Technology Interested in joining the MIRG? Please contact Aaron Yamniuk (MIRG Chair) at aaron.yamniuk@bms.com

ABSTRACT Session 1 Introduction to a Protein Interaction System used for Quantitative Evaluation of Biomolecular Interactions - Aaron Yamniuk, Bristol-Myers Squibb A central goal of molecular biology is the determination of biomolecular function. This comes largely from a knowledge of the non-covalent interactions that biological small and macromolecules experience. The fundamental mission of the Molecular Interactions Research Group (MIRG) of the ABRF is to show how solution biophysical tools are used to quantitatively characterize molecular interactions, and to educate the ABRF members and scientific community on the utility and limitations of core technologies such as biosensors, microcalorimetry or analytical ultracentrifugation, for evalution of such interactions. To this end, the MIRG developed a model system for the quantitative analysis of protein-protein interactions, and validated the system using several orthogonal techniques. In this presentation (MIRG Session 1), the details of the protein-protein interaction system will be described, along with an summary of experimental data obtained in MIRG laboratories. The quantitation of the binding affinity was found to be reproducible in multiple MIRG laboratories and using several techniques such as surface plasmon resonance, isothermal titration calorimetry, and analytical ultracentrifugation. In addition, the proteins were shown to be highly stable and soluble, suggesting that the system was suitable for use in benchmarking. Therefore, in late 2012 the MIRG conducted a benchmarking study to evaluate the capabilities of different laboratories and instrumentation to quantitatively characterize the binding affinity and stiochiometry for the model MIRG system, the results of which will be summarized in the subsequent presentation (MIRG Session 2). 17